Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TRF2 as novel marker of tumor response to taxane-based therapy: from mechanistic insight to clinical implication.
Iachettini S, Terrenato I, Porru M, Di Vito S, Rizzo A, D'Angelo C, Petti E, Dinami R, Maresca C, Di Benedetto A, Palange A, Mulè A, Santoro A, Palazzo A, Fuso P, Stoppacciaro A, Vici P, Filomeno L, Di Lisa FS, Arcuri T, Krasniqi E, Fabi A, Biroccio A, Zizza P. Iachettini S, et al. Among authors: porru m. J Exp Clin Cancer Res. 2024 Mar 9;43(1):75. doi: 10.1186/s13046-024-02998-w. J Exp Clin Cancer Res. 2024. PMID: 38459559 Free PMC article.
Targeting of H19/cell adhesion molecules circuitry by GSK-J4 epidrug inhibits metastatic progression in prostate cancer.
Pecci V, Troisi F, Aiello A, De Martino S, Carlino A, Fiorentino V, Ripoli C, Rotili D, Pierconti F, Martini M, Porru M, Pinto F, Mai A, Bassi PF, Grassi C, Gaetano C, Pontecorvi A, Strigari L, Farsetti A, Nanni S. Pecci V, et al. Among authors: porru m. Cancer Cell Int. 2024 Feb 5;24(1):56. doi: 10.1186/s12935-024-03231-6. Cancer Cell Int. 2024. PMID: 38317193 Free PMC article.
DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study.
Bon G, Krasniqi E, Porru M, D'Ambrosio L, Scalera S, Maugeri-Saccà M, Di Lisa FS, Filomeno L, Arcuri T, Botticelli A, Santini D, Fabbri MA, D'Auria G, Pulito C, Blandino G, Marchiò C, Barba M, Ciliberto G, Vici P, Pizzuti L. Bon G, et al. Among authors: porru m. Neoplasia. 2023 Nov;45:100937. doi: 10.1016/j.neo.2023.100937. Epub 2023 Sep 26. Neoplasia. 2023. PMID: 37769528 Free PMC article.
Fluorescent nanodiamonds as innovative delivery systems for MiR-34a replacement in breast cancer.
Abate M, Lombardi A, Luce A, Porru M, Leonetti C, Bocchetti M, Campani V, De Rosa G, Graziano SF, Nele V, Cardile F, Marino FZ, Franco R, Ronchi A, Scrima M, Sperlongano R, Alfano R, Misso G, Amler E, Caraglia M, Zappavigna S. Abate M, et al. Among authors: porru m. Mol Ther Nucleic Acids. 2023 Jun 19;33:127-141. doi: 10.1016/j.omtn.2023.06.012. eCollection 2023 Sep 12. Mol Ther Nucleic Acids. 2023. PMID: 37449042 Free PMC article.
MiR-182-3p targets TRF2 and impairs tumor growth of triple-negative breast cancer.
Dinami R, Pompili L, Petti E, Porru M, D'Angelo C, Di Vito S, Rizzo A, Campani V, De Rosa G, Bruna A, Serra V, Mano M, Giacca M, Leonetti C, Ciliberto G, Tarsounas M, Stoppacciaro A, Schoeftner S, Biroccio A. Dinami R, et al. Among authors: porru m. EMBO Mol Med. 2023 Jan 11;15(1):e16033. doi: 10.15252/emmm.202216033. Epub 2022 Nov 25. EMBO Mol Med. 2023. PMID: 36426578 Free PMC article.
TRF2 cooperates with CTCF for controlling the oncomiR-193b-3p in colorectal cancer.
Dinami R, Petti E, Porru M, Rizzo A, Ganci F, Sacconi A, Ostano P, Chiorino G, Trusolino L, Blandino G, Ciliberto G, Zizza P, Biroccio A. Dinami R, et al. Among authors: porru m. Cancer Lett. 2022 May 1;533:215607. doi: 10.1016/j.canlet.2022.215607. Epub 2022 Feb 28. Cancer Lett. 2022. PMID: 35240232 Free article.
66 results